GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review

1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Johnson & Johnson
  • Novartis AG
  • Revitin Life Sciences LLC
  • MORE
GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Oct 29, 2018: GSK announces positive phase 3 results for daprodustat in patients with anaemia associated with chronic kidney disease
Oct 25, 2018: GSK opens new Ellipta plant in Scotland
Oct 23, 2018: MBDA, GSK and Airbus team up for Generation Stevenage event
Oct 23, 2018: GlaxoSmithKline opens new £54 million facility in north-east town
Oct 22, 2018: GSK invests in Montrose

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Eli Lilly and Co
  • Johnson & Johnson
  • Novartis AG
  • Revitin Life Sciences LLC
  • MORE
List of Tables
List of Figures
Section 1 - About the Company
GlaxoSmithKline Plc - Key Facts
GlaxoSmithKline Plc - Key Employees
GlaxoSmithKline Plc - Key Employee Biographies
GlaxoSmithKline Plc - Major Products and Services
GlaxoSmithKline Plc - History
GlaxoSmithKline Plc - Company Statement
GlaxoSmithKline Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
GlaxoSmithKline Plc - Business Description
Business Segment: Consumer Healthcare
Overview
Performance
Key Stats
Business Segment: Pharmaceuticals
Overview
Performance
Key Stats
Business Segment: Vaccines
Overview
Performance
Key Stats
Geographical Segment: International
Performance
Geographical Segment: The UK
Performance
Geographical Segment: US
Performance
R&D Overview
GlaxoSmithKline Plc - Corporate Strategy
GlaxoSmithKline Plc - SWOT Analysis
SWOT Analysis - Overview
GlaxoSmithKline Plc - Strengths
GlaxoSmithKline Plc - Weaknesses
GlaxoSmithKline Plc - Opportunities
GlaxoSmithKline Plc - Threats
GlaxoSmithKline Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
GlaxoSmithKline Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 22, 2018: GlaxoSmithKline Pharmaceuticals delivers strong H1 performance; H1 Revenue up 8% and PAT higher by 21%
Oct 22, 2018: GSK invests in Montrose
Oct 21, 2018: GSK presents new efficacy and safety data of an anti GM-CSF antibody in patients with rheumatoid arthritis
Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont
Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont
Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont
Oct 18, 2018: 18 October 2018 ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV Priority review voucher used with NDA submission with anticipated target action date of six mont
Oct 02, 2018: GSK updates policy for working with healthcare professionals
Oct 02, 2018: GSK updates policy for working with healthcare professionals
Oct 01, 2018: Theraflu PowerPods launches Pods For convenient cold and flu symptom relief
Section 6 – Appendix
Methodology
Ratio Definitions
Contact Us
Disclaimer

List of Tables
GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc, Key Employees
GlaxoSmithKline Plc, Key Employee Biographies
GlaxoSmithKline Plc, Major Products and Services
GlaxoSmithKline Plc, History
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Joint Venture
GlaxoSmithKline Plc, Key Competitors
GlaxoSmithKline Plc, Ratios based on current share price
GlaxoSmithKline Plc, Annual Ratios
GlaxoSmithKline Plc, Interim Ratios
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
GlaxoSmithKline Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
GlaxoSmithKline Plc, Performance Chart (2013 - 2017)
GlaxoSmithKline Plc, Ratio Charts
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Sanofi
  • Revitin Life Sciences LLC
  • Pfizer Inc
  • Novartis AG
  • Merck & Co Inc
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • AstraZeneca Plc
  • Amgen Inc
  • AbbVie Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll